Literature DB >> 31632573

PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.

Doudou Huang1, Lin Tang1, Fang Yang1, Juan Jin1, Xiaoxiang Guan1,2.   

Abstract

p110α is an important subunit of phosphatidylinositol-3-kinases (PI3Ks) encoded by PIK3CA. Though PI3Ks are known as crucial regulators of cellular growth and proliferation, the function of PIK3CA mutations in fulvestrant resistance remains elusive. Thus, this study aimed to investigate the roles of PIK3CA mutations in fulvestrant resistance and tumor progression. Using circulating tumor DNA (ctDNA) from four fulvestrant-resistant patients, we found three of them were PIK3CA mutated, one with a novel PIK3CA mutation (p.R115P). In vitro experiments further evaluated the functions of those mutations and underlying mechanisms. We identified PIK3CA mutations could not only confer to fulvestrant resistance, but also promote cell proliferation and migration. Inhibition of corresponding activated pathways could effectively suppress cell growth. AJTR
Copyright © 2019.

Entities:  

Keywords:  Fulvestrant resistance; PIK3CA mutation; estrogen receptor-positive breast cancer

Year:  2019        PMID: 31632573      PMCID: PMC6789267     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  29 in total

1.  PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.

Authors:  Sauveur-Michel Maira
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

2.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Authors:  Nicholas C Turner; Cynthia Huang Bartlett; Massimo Cristofanilli
Journal:  N Engl J Med       Date:  2015-10-22       Impact factor: 91.245

3.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 4.  Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.

Authors:  Richard J Pietras
Journal:  Oncologist       Date:  2006 Jul-Aug

Review 5.  Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer.

Authors:  Doudou Huang; Fang Yang; Yucai Wang; Xiaoxiang Guan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-23       Impact factor: 10.680

6.  Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

Authors:  B Markman; J Tabernero; I Krop; G I Shapiro; L Siu; L C Chen; M Mita; M Melendez Cuero; S Stutvoet; D Birle; O Anak; W Hackl; J Baselga
Journal:  Ann Oncol       Date:  2012-02-22       Impact factor: 32.976

7.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Authors:  Christina Gewinner; Zhigang C Wang; Andrea Richardson; Julie Teruya-Feldstein; Dariush Etemadmoghadam; David Bowtell; Jordi Barretina; William M Lin; Lucia Rameh; Leonardo Salmena; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

Review 8.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

9.  Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.

Authors:  Luca Magnani; Alexander Stoeck; Xiaoyang Zhang; András Lánczky; Anne C Mirabella; Tian-Li Wang; Balázs Gyorffy; Mathieu Lupien
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

10.  Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.

Authors:  Sherri Z Millis; Sadakatsu Ikeda; Sandeep Reddy; Zoran Gatalica; Razelle Kurzrock
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

View more
  6 in total

1.  PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis.

Authors:  Yanyan Han; Fang Li; Jun Xie; Yi Wang; Hua Zhang
Journal:  Cancer Manag Res       Date:  2020-10-13       Impact factor: 3.989

2.  Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors.

Authors:  Paula Martínez-Fernández; Patricia Pose; Raquel Dolz-Gaitón; Arantxa García; Inmaculada Trigo-Sánchez; Enrique Rodríguez-Zarco; MJose Garcia-Ruiz; Ibon Barba; Marta Izquierdo-García; Jennifer Valero-Garcia; Carlos Ruiz; Marián Lázaro; Paula Carbonell; Pablo Gargallo; Carlos Méndez; Juan José Ríos-Martín; Alberto Palmeiro-Uriach; Natalia Camarasa-Lillo; Jerónimo Forteza-Vila; Inés Calabria
Journal:  J Pers Med       Date:  2021-04-29

3.  PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.

Authors:  Huayu Hu; Junyong Zhu; Yuting Zhong; Rui Geng; Yashuang Ji; Qingyu Guan; Chenyan Hong; Yufan Wei; Ningning Min; Aiying Qi; Yanjun Zhang; Xiru Li
Journal:  Ann Transl Med       Date:  2021-03

Review 4.  Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.

Authors:  Chao Dong; Jiao Wu; Yin Chen; Jianyun Nie; Ceshi Chen
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

Review 5.  Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options.

Authors:  Constanze Elfgen; Vesna Bjelic-Radisic
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

Review 6.  Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.

Authors:  Rinath Jeselsohn; Elgene Lim; Teesha Downton; Fiona Zhou; Davendra Segara
Journal:  Drug Des Devel Ther       Date:  2022-09-02       Impact factor: 4.319

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.